Related Experiment Video

Updated: Jul 20, 2026

Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier
07:53

Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier

Published on: April 26, 2016

Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma

Agop Y Bedikian1, Michael Millward, Hubert Pehamberger

  • 1University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|September 13, 2006
PubMed
Abstract

Insights

Targeting Bcl-2 with oblimersen sodium improved chemotherapy efficacy in advanced melanoma patients. The combination therapy showed increased progression-free survival and overall survival in patients without elevated baseline serum LDH.

Area of Science:

  • Oncology
  • Melanoma Research
  • Pharmacology

Background:

  • Chemotherapy resistance in melanoma is often linked to antiapoptotic effects mediated by Bcl-2 protein.
  • Targeting Bcl-2 offers a potential strategy to overcome this resistance.

Purpose of the Study:

  • To evaluate if targeting Bcl-2 with oblimersen sodium could enhance the efficacy of systemic chemotherapy in advanced melanoma patients.
  • To assess the impact of oblimersen sodium combined with dacarbazine on patient survival and response rates.

Main Methods:

  • A randomized trial involving 771 chemotherapy-naïve advanced melanoma patients.
  • Patients received either dacarbazine alone or dacarbazine preceded by oblimersen sodium.
  • Stratification based on performance status, liver metastases, disease site, and serum lactate dehydrogenase (LDH).

Main Results:

  • The combination of oblimersen sodium and dacarbazine showed a trend toward improved overall survival (9.0 vs 7.8 months).
  • Significant increases were observed in progression-free survival (2.6 vs 1.6 months), overall response (13.5% vs 7.5%), and complete response rates.
  • Oblimersen significantly increased overall survival in patients with normal baseline serum LDH (11.4 vs 9.7 months).

Conclusions:

  • Adding oblimersen sodium to dacarbazine significantly improved multiple clinical outcomes in advanced melanoma.
  • The combination therapy demonstrated increased overall survival, particularly in patients without elevated baseline serum LDH.
  • While neutropenia and thrombocytopenia increased, serious infections and bleeding events were not elevated.

More Related Videos

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis07:41

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Skin Cancer01:30

Skin Cancer

Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...